Botulinum toxin type A for the prevention of headaches in adults with chronic migraine

  • Technology appraisal guidance
  • TA260
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Warwick Evidence:

  • Royle P, Cummins E, Walker C et al, Evidence review group report: Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine, December 2011

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • Allergan

II Professional/specialist and patient/carer groups:

  • Migraine Action

  • Migraine Trust

  • Association of British Neurologists

  • British Association for Study of Headache

  • British Pain Society

  • Institute of Neurology

  • Migraine in Primary Care Advisors

  • Primary Care Neurology Society

  • Royal College of Anaesthetists

  • Royal College of Nursing

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

III Other consultees:

  • Department of Health

  • Welsh Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety – Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare Products Regulatory Agency

  • National Hospital for Neurology and Neurosurgery

  • Warwick Evidence

  • National Institute for Health Research Health Technology Assessment Centre

  • National Clinical Guidelines Centre

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on botulinum toxin type A by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Fayyaz Ahmed, Consultant Neurologist, nominated by British Association for the Study of Headache – clinical specialist

  • Dr Paul Shanahan, Consultant Neurologist, nominated by the National Hospital for Neurology and Neurosurgery – clinical specialist

  • Elaine Ransome, nominated by the Migraine Trust – patient expert

  • Wendy Thomas, Chief Executive of Migraine Trust, nominated by the Migraine Trust – patient expert

D Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Allergan